Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Published byAndrés Prado Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of."— Presentation transcript:

1 Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel.
TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. (A) Experimental design and chemotherapy scheme. (B) Mouse models of breast carcinoma and cohort sizes. (C and D) TMEM scores in the PyMT transplantation model (C) and the HT17 xenograft model (D), treated with vehicle control, rebastinib, paclitaxel, or a combination of rebastinib with paclitaxel. Mann-Whitney U test. (E and F) Perivascular TIE2hi/VEGFhi macrophages quantified in 10 HPFs in the PyMT transplantation model (E) or in the HT17 xenograft model (F), treated with vehicle control rebastinib, paclitaxel, or a combination of rebastinib with paclitaxel. Mann-Whitney U test. (G and H) CTCs per milliliter of blood collected before sacrifice (day 15) of mice [PyMT transplantation (G); HT17 xenograft (H)]. Values normalized to the control group in each case to account for intercohort variability. Mann-Whitney U test. (I) Incidence of bursting (at least one complete event during 4.5 hours of imaging per mouse) in paclitaxel-treated MMTV-PyMT/Dendra2 cfms-CFP mice that either received or did not receive rebastinib. (J) Frequency of bursting in paclitaxel-treated MMTV-PyMT/Dendra2 cfms-CFP mice that either received or did not receive rebastinib. Mann-Whitney U test. (K) Proposed model of chemotherapy-induced prometastatic changes and cancer cell dissemination. Chemotherapy treatment increases the density of TIE2hi/VEGFhi macrophages within the primary tumor. In addition to inducing angiogenesis, these macrophages assemble active TMEM structures. Chemotherapy treatment also increases expression of the actin-regulatory protein MENAINV isoform in tumor cells due to their contact with infiltrating macrophages, which makes these cancer cells highly migratory and invasive. Upon arriving at the blood vessels, some of the MENAINV-expressing cancer cells assemble active TMEM sites, which other MENAINV-expressing cells then use to intravasate. Together, chemotherapy-mediated MENAINV overexpression and TMEM assembly in breast cancer contribute to TMEM-dependent cancer cell dissemination and distant metastasis. Targeting the function of TMEM-associated macrophage subpopulation by a TIE2 inhibitor counteracts TMEM-mediated cancer cell dissemination induced by chemotherapy treatment. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Download ppt "Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of."

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
Fibroblast activation in WT and NFATc2-deficient mice.

Fibroblast activation in WT and NFATc2-deficient mice.
Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.
CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.
FIP200 maintains microRNA1198-5p expression via Ago2 in naïve T cells.

FIP200 maintains microRNA1198-5p expression via Ago2 in naïve T cells.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.
The TGF-β pathway is activated in the skin after C

The TGF-β pathway is activated in the skin after C
FIP200 controls Bak expression via maintaining microRNA1198-5p expression. FIP200 controls Bak expression via maintaining microRNA1198-5p expression. (A)

FIP200 controls Bak expression via maintaining microRNA1198-5p expression. FIP200 controls Bak expression via maintaining microRNA1198-5p expression. (A)
Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Similar presentations

Ads by Google